There are currently 1891 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SPECT/CT for the Characterization of Renal Masses
NCT03996850
Recruiting
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Kidney Neoplasm, Renal Mass
Register for Updates
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects with an IPAA (PROF)
NCT05938465
Recruiting
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Ileal Pouch
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: UCLA, Los Angeles, California
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Los Angeles, California
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479
Recruiting
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/21/2025
Locations: Research Site, Los Angeles, California
Conditions: Migraine
Register for Updates
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
NCT04703101
Recruiting
This phase I trial investigates how well short-course radiation therapy followed by combination chemotherapy works in treating patients with stage II-III rectal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as leucovorin, fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sho... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Register for Updates
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
NCT05558904
Recruiting
The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. S... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Yesenia Calzada, Los Angeles, California
Conditions: Lung Adenocarcinoma
Register for Updates
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
NCT04712851
Recruiting
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
02/21/2025
Locations: University of California at Los Angeles / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Register for Updates
Stem Cell Transplantation in Crohn's Disease
NCT04224558
Recruiting
Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit. For severe Crohn's disease, there is an experimental treatment called "high dose immunoablation" followed by autologous hematopoietic stem cell transplantation (HSCT). This study removes over active lymphocytes (immunoablation) and replaces them using blood stem cells that have been taken from the patient's own body. The aim of the study is to reset o... Read More
Gender:
ALL
Ages:
Between 13 years and 28 years
Trial Updated:
02/20/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Crohn Disease
Register for Updates
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
NCT05027477
Recruiting
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.
Gender:
MALE
Ages:
Between 40 years and 80 years
Trial Updated:
02/20/2025
Locations: Urology Group of Southern California, Los Angeles, California +2 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
HM15136 (efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years with Congenital Hyperinsulinism (CHI)
NCT04732416
Recruiting
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/20/2025
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Congenital Hyperinsulinism
Register for Updates
Losartan + Sunitinib in Treatment of Osteosarcoma
NCT03900793
Recruiting
This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
02/20/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Osteosarcoma
Register for Updates